Oramed Pharmaceuticals Inc. (ORMP): ANSOFF MATRIX [Dec-2025 Updated]

You're looking at a company with a clear runway-Oramed Pharmaceuticals Inc. (ORMP) has over $100 million in cash to fund 2025 operations, which gives them the breathing room to make some big strategic moves. Honestly, looking at their plan mapped out on the Ansoff Matrix, it's clear they aren't just sticking to the script; they're attacking growth from every angle, from pushing their POUYA platform harder in the US to potentially launching oral GLP-1 analogs and even eyeing non-pharma supplements. I've seen plenty of companies with this much capital, but ORMP's four-pronged approach-penetration, development, new products, and even diversification-is worth a deep dive to see where the real near-term upside is hiding. Keep reading to see how these four paths map out their next few years.

Oramed Pharmaceuticals Inc. (ORMP) - Ansoff Matrix: Market Penetration

You're looking at how Oramed Pharmaceuticals Inc. (ORMP) can drive growth by selling more of its existing POUYA platform technology into its current US market space. This is about maximizing penetration right where you already have a presence.

For increasing licensing deals for the POUYA platform in the US, the financial context from the nine months ended September 30, 2025, shows a strong operational base. Oramed Pharmaceuticals Inc. reported a net income (pre-tax) of $65.0 million for that nine-month period, a significant shift from a net loss of $6.1 million in the same period last year. This financial flexibility definitely helps in structuring attractive licensing terms.

To secure more co-development partnerships with existing US pharma clients, consider the balance sheet strength. Total assets grew 42% year-over-year, reaching $220.5 million from $155.3 million. Also, the company completed the full repayment from Scilex, receiving approximately $27 million during the period, which brought the total repayment to $100 million.

Focus marketing efforts on the platform's non-insulin applications requires resource allocation. Research and Development (R&D) expenses for the nine months ended September 30, 2025, were $4.4 million, down from $4.9 million previously. General and Administrative (G&A) expenses, however, rose from $4.3 million to $5.0 million, which could reflect increased overhead supporting broader platform exploration.

Deepening relationships with key opinion leaders (KOLs) in oral drug delivery technology is supported by the company's recent strategic moves, like the investment in Alpha Tau Medical Ltd. An affiliate of Oramed Pharmaceuticals Inc. purchased approximately 14.1 million Alpha Tau shares at $2.612 per share, totaling an initial investment of $36.9 million. By September 30, 2025, this position of 14.4 million shares was valued at approximately $64.8 million, representing a gain of $27.1 million on the investment.

Offering platform-use incentives to smaller biotech firms in the existing market is a capital-intensive strategy. The company's strong financial standing, including the $100 million total cash repayment from Scilex, provides the necessary capital buffer to offer favorable terms. The basic earnings per share for the nine-month period stood at $1.30.

Here are the key financial metrics underpinning the current operational capacity:

• Basic earnings per share for the nine months ended September 30, 2025: $1.30
• Diluted earnings per share for the nine months ended September 30, 2025: $1.26
• Total assets as of September 30, 2025: $220.5 million
• Total assets as of September 30, 2024 (implied): $155.3 million
• Total cash received from Scilex repayment: $100 million
• R&D expenses for nine months 2025: $4.4 million

The following table summarizes the financial context relevant to market penetration activities as of the nine months ended September 30, 2025:

To advance the oral insulin program, Oramed Pharmaceuticals Inc. is initiating a 60-patient, US-based trial to validate the formulation in high-responder subgroups.

• Planned US Phase 3 trial patient count for oral insulin: 60 patients
• Initial investment in Alpha Tau Medical on April 24, 2025: $36.9 million
• Total Alpha Tau shares held as of September 30, 2025: 14.4 million shares
• Total cash received from Scilex: $100 million

Oramed Pharmaceuticals Inc. (ORMP) - Ansoff Matrix: Market Development

Target Asian markets, especially China and Japan, for platform licensing.

• Marketing Authorization Application submitted by HTIT for oral insulin capsule in China.
• OraTech, the former joint venture, was expected to receive royalties from China sales.
• The joint venture agreement with Hefei Tianhui Biotech Co., Ltd. was terminated in October 2025.

Form strategic alliances with European pharmaceutical companies for POUYA adoption.

Apply the oral delivery platform to non-diabetic therapeutic areas like NASH or obesity.

• The global market for drugs to treat NASH is expected to reach $84 billion by 2029.
• The Non-alcoholic Steatohepatitis Drugs Pipeline Market Size in 2025 is estimated at USD 479.7 million.
• The Anti-obesity market is on track to reach $200 billion in annual sales by the early 2030s.
• Oramed Pharmaceuticals Inc. is developing ORMD-0901, an oral GLP-1 receptor agonist, for obesity.

Present POUYA at global pharmaceutical technology conferences to attract new partners.

Explore government grants for oral vaccine delivery in developing nations.

• Oramed's subsidiary, Oravax Medical Inc., is focused on developing oral vaccines.
• The company received approximately $27 million from the full repayment of its Scilex strategic investment during the period.
• Oramed Pharmaceuticals Inc. reported basic earnings per share of $1.30 for the nine-month period.

Oramed Pharmaceuticals Inc. (ORMP) - Ansoff Matrix: Product Development

You're looking at the engine room of Oramed Pharmaceuticals Inc. (ORMP), where capital deployment directly translates into pipeline advancement. The focus here is on creating new products or significantly improving existing ones using the core Protein Oral Delivery (POD) technology.

For the nine months ended September 30, 2025, Oramed Pharmaceuticals Inc. reported Research and Development (R&D) expenses of \$4.4 million, a decrease from \$4.9 million in the comparable prior period. This capital is the fuel for the specific product development initiatives you mentioned. To give you context on the commitment to the platform, the company noted that since January 2023, it had invested \$17.8 million in R&D to advance its refined oral insulin program and share buybacks.

The pipeline reflects a clear strategy of converting injectable biologics into oral dosage forms. Here's a look at the current state of key candidates supporting this development strategy:

• The oral GLP-1 analog, ORMD-0901, has advanced beyond preclinical stages, completing a Phase I pharmacokinetic (PK) study.
• This Phase I study involved up to 15 healthy subjects and evaluated ORMD-0901 against placebo and the injectable GLP-1 analog, Byetta®.
• ORMD-0801, the oral insulin capsule, remains in Phase III for Diabetes and is also being evaluated in Phase II for Nonalcoholic Steatohepatitis (NASH).
• Oramed Pharmaceuticals Inc. is also developing an oral leptin capsule, aiming to evaluate glucagon reduction in Type 1 diabetes, with a long-term goal of addressing weight loss.

The platform itself is protected by a growing portfolio of intellectual property. As of the 2024 Annual Report, Oramed Pharmaceuticals Inc. held 140 granted patents. Furthermore, the company maintained 26 patent applications pending, with potential expiration dates ranging from 2026 through 2039 if granted. This IP fortification supports not only existing peptide programs but also future platform improvements, including a U.S. patent granted for oral compositions comprising insulin in combination with glucagon-like peptide 1 (GLP-1).

The financial flexibility supporting these development efforts is substantial. Total assets for Oramed Pharmaceuticals Inc. grew 42% year-over-year to \$220.5 million as of September 30, 2025, with cash and cash equivalents reported at approximately \$210 million. This financial position is intended to provide the flexibility to pursue strategic opportunities while advancing the oral drug delivery platform.

Here's a snapshot of the pipeline assets and their current reported development stage:

The investment in R&D capital for optimizing the platform is implicitly tied to the overall operating expenses. The company's general and administrative (G&A) expenses increased to \$5.0 million for the nine-month period, while R&D was \$4.4 million.

The strategy to accelerate screening, though not explicitly detailed with a CRO name and cost, is funded by this R&D budget and the overall financial strength, which saw a pre-tax net income of \$65.0 million for the nine months ended September 30, 2025.

The intellectual property strategy is broad, covering 140 granted patents and 26 pending applications, which supports platform improvements across various molecules.

Finance: review Q4 2025 R&D spend against the \$17.8 million three-year investment target by end of January.

Oramed Pharmaceuticals Inc. (ORMP) - Ansoff Matrix: Diversification

Oramed Pharmaceuticals Inc. is pursuing diversification through strategic capital deployment, moving beyond its core drug delivery platform focus.

Establish a wholly-owned subsidiary focused on non-pharmaceutical oral supplements.

• No specific revenue or investment figures available for a non-pharmaceutical oral supplements subsidiary as of the nine months ended September 30, 2025.

Commercialize a diagnostic tool related to gut absorption or drug bioavailability.

• The company's net income (pre-tax) for the nine months ended September 30, 2025, was reported as $65.0 million, compared to a net loss of $6.1 million in the same prior period.
• Total assets grew by 42% year-over-year, reaching $220.5 million from $155.3 million.

License the POUYA technology outside of human therapeutics, perhaps for veterinary medicine.

The financial structure supporting this diversification is underpinned by investment returns. For example, the company received approximately $27 million during the nine months ended September 30, 2025, completing a full repayment of $100 million from a strategic investment.

Acquire a small, revenue-generating medical device company to stabilize cash flow.

The company's diversification strategy heavily involves its investment portfolio, which generated substantial unrealized fair-value gains, contributing to the nine-month net income of $65.0 million.

Offer specialized consulting services on oral drug formulation to other biotechs.

• General and Administrative (G&A) expenses increased from $4.3 million to $5.0 million in the nine-month period ended September 30, 2025.
• Research and Development (R&D) expenses decreased from $4.9 million to $4.4 million in the same nine-month period.

Oramed Pharmaceuticals Inc. formed the joint venture OraTech Pharmaceuticals, Inc., focused on oral insulin development, with planned U.S. Phase 3 trials. This JV structure is expected to result in Oramed receiving royalty streams over the next decade from multiple Scilex products, including $400,000 due for Q4 2024 sales. Basic earnings per share for the nine months ended September 30, 2025, was $1.30.